Physician profile
Summer Mitchell
NPI 1538558473
$3,098.84
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $882 · 2023: $633 · 2024: $419 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.29 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,003.59 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $682.67 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $260.67 | 2021-2023 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $224.90 | 2021-2025 | Verquvo |
| Medtronic, INC. | $201.98 | 2021-2024 | Corevalve Evolut R |
| Amgen INC. | $141.30 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.91 | 2021-2023 | Lifevest |
| Shockwave Medical, INC | $67.27 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $57.37 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.39 | 2023-2024 | Camzyos, Eliquis |
| Terumo Medical Corporation | $39.09 | 2022-2024 | Navicross |
| Kestra Medical Technology Services, INC. | $36.66 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $31.86 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $27.05 | 2025 | |
| Abiomed | $26.91 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $26.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.13 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $20.37 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $18.74 | 2024 | Evkeeza |
| Scpharmaceuticals INC. | $16.47 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.13 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $15.06 | 2024 | Inspire |
| Boston Scientific Corporation | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.